🔗 Share this article

While America undertakes unprecedented revisions to its immunization schedules, an unexpected name has emerged unexpectedly: Høeg, a US-based sports physician and public health researcher who initially gained attention by casting doubt on Covid vaccines in the global health crisis and has focused upon possible fatalities after COVID-19 immunization in her brief position at the Food and Drug Administration.

Planned Shifts to Childhood Immunization Program

Agency leaders were set to unveil radical revisions to the pediatric vaccine schedule in December, aligning the US with the Danish immunization schedule, according to reports – a major change that would place the US at odds with many the global community with no evidence for improved outcomes. The announcement has been postponed until the next year.

In place of the top vaccines chief, Dr. Høeg is listed to speak at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to run the division this calendar year.

Consolidating Power at the FDA

This interim role may indicate a closer partnership between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad consolidate power at the agency – and it points to a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric vaccine recommendations in the US so as to align more similar to Denmark's approach, a country with comprehensive healthcare and a population approximately the size of Wisconsin’s.

To date comments, she has continued to focus on vaccines – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Questions Over Expertise

Høeg has little discernible background in pharmaceutical research, oversight or administrative roles, which has been standard for past heads of the biologics center. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for running the CDER, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in leading a sizeable institution. She lacks background in industry regulation.”

Past heads of CBER would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she lacks the type of experience that former directors who ran CBER have had.”

CDER has an immense workload at the agency, the former commissioner stated.

“The public just pays attention on the new drug program, but the generic drug division authorizes numerous generic medications. There is also a biosimilars division, non-prescription drug unit and so forth, and every single one need to be looked after,” she noted. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial administrative aspect to the role, which oversees in excess of 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” she concluded.

Agency Reaction and Controversial Initiatives

Regarding inquiries about Dr. Høeg's credentials and whether this assignment indicates increased cooperation among agency officials on immunizations, a press secretary said that the “inquiries rely on incorrect presumptions”.

“This background matches the responsibilities of her job,” the official said, citing the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s new expedited review system, a disputed expedited drug-approval program that apparently worried her predecessors. “How are these drugs being selected for this expedited pathway? Who takes the choices?” Howard said. “There’s a lot of lack of transparency occurring at the agency right now.”

Overall, he remarked, “the agency appears to be shifting towards laxer rules of all drugs, with the exception of vaccines.”

Public History on Immunizations

With immunizations, Høeg has a clearer, if troubling, track record, Howard observe. She authored a research paper using unconfirmed public submissions to estimate the incidence of heart inflammation after COVID-19 vaccination. She counseled the Florida top health official Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Included in her “policy goals” for the incoming administration featured altering rules for novel immunizations and discontinuing “unnecessary” immunizations, she remarked following the vote on a online show. At the agency, Dr. Høeg has reportedly proposed preventing teenage boys from obtaining Covid vaccines.

“She is an thorough dogmatist who starts off with her beliefs and reverse-engineers to retrofit the science in a very misleading, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of other skeptics, {like|